3rd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

Firm
Client
Income
—
Expenses
$420,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to various patent reform bills (H.R.9, S.632, S.1137).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE New Professional Staff for Rep. Tom Davis; Clerk for Rep. Todd Platts; Intern for Sen. Rick Santorum
MARY LACEY REUTHER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1137 (114th), S. 632 (114th), H.R. 9 (114th)

Taxation/Internal Revenue Code TAX

Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th), H.R. 2739 (114th), S. 1566 (114th)

Medicare/Medicaid MMM

Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 512 (114th), H.R. 5122 (114th), H.R. 1178 (114th), S. 1466 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.